Last week the Cytel Blog discussed the benefits of using the Adaptive Maximizing Design [AM Design] for dose-finding trials involving clinical utility limiting therapies. However, there are other ways that a dose-finding trial can make use of frequent-adaptation maximizing designs. Here we look at what happens to early phase clinical development when an AM Design combines with another adaptive design that is slowly gaining popularity, namely the Sequential Parallel Comparison Design.
Last week the Cytel Blog discussed the benefits of using the Adaptive Maximizing Design [AM Design] for dose-finding trials involving clinical utility limiting therapies . Clinical utility limiting therapies are those in which high levels of adverse side effects place limits on dose selection. For example, when testing a new pain medication, randomization into a high dose arm is likely to cause nausea and vomiting. Randomization into a low dose-arm, by contrast, will not alleviate a sufficient amount of pain.
Given that we do not know the correct dose to administer to a patient prior to a dose-finding trial, it is worthwhile to invest in a trial design which predictably randomizes as many patients as possible into dose-arms near or at the correct dose. A new paper published in Therapeutic Innovation & Regulatory Science argues that the AM Design achieves this, particularly when compared to a conventional trial .
A natural question arises as to whether or not such a design will make the trial more expensive. One of the benefits of the AM Design is that it has been known to increase the likelihood of finding the right dose, when compared to a conventional trial. As a result, it is a good investment when preparing for Phase 3.
AM Designs can also combine with other adaptive clinical trial designs to determine optimal clinical utility even faster.
One of our clients recently came to us for a new drug that would benefit from a Sequential Parallel Comparison Design [SPCD]. SPCD’s are two-stage designs meant for therapeutic areas known to have high levels of placebo response (e.g. psychiatry.) The second stage of an SPCD trial offers the chance to compare efficacy only amongst placebo non-responders (i.e. the first stage establishes which patients do and do not respond to placebo; the second stage compares responses of the non-responders.)
SPCD are sometimes associated with Phase 3 trials. However, statisticians are developing new uses of the SPCD for the purposes of dose-finding .
Working off of a familiar SPCD Model, Cytel designed the two stages of the SPCD to reflect proof-of-concept and dose-finding. The second, dose-finding stage of the SPCD was then designed as an AM Design. This leveraged the benefits of the AM Design improve dose-selection, while also utilizing the hallmarks of the SPCD (i.e. smaller sample size). The overall result was an estimated 3-6 month expedited development time.